Quidel Announces Early Termination of the Hart-Scott-Rodino Waiting Period for Its Pending Acquisition of Alere’s Triage® ...
September 28 2017 - 2:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider
of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems, announced that it has
received notice from the Federal Trade Commission granting early
termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, with respect to
Quidel’s pending acquisition of Alere Inc.’s Triage B-type
natriuretic peptide assay business run on Beckman Coulter analyzers
(the “BNP business”). The acquisition of the BNP business by Quidel
remains subject to the completion of Abbott’s acquisition of Alere,
as well as other regulatory approvals and other customary closing
conditions.
Quidel’s acquisition of Alere’s Triage MeterPro business is not
affected by the early termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, and remains
subject to the completion of Abbott’s acquisition of Alere, as well
as regulatory approvals and other customary closing conditions.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel’s research and development engine is
also developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
Forward-Looking Statements
This press release contains certain forward-looking statements.
These matters are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
anticipated or implied. These risks and uncertainties include: the
ability to successfully consummate the Company’s acquisition of the
BNP business, and the related pending acquisition of Alere’s
Triage® MeterPro assets (collectively, the “acquisitions”) on a
timely basis, if at all, including the satisfaction of the closing
conditions of the acquisitions (including consummation of Abbott’s
acquisition of Alere); the ability to receive all other regulatory
approvals for the acquisitions on a timely basis, if at all; the
ability to satisfy the conditions of and obtain financing to
complete the acquisition of the Triage® MeterPro assets (the
“Triage business”); the conditions of the credit markets and the
Company’s ability to fund the acquisitions on acceptable terms; the
risk that disruptions will occur from the acquisitions that will
harm the Company’s business, the Triage business or the BNP
business; any disruptions or threatened disruptions to the
relationships of the Company, the Triage business or the BNP
business with their respective distributors, suppliers, customers
and employees; the Company’s ability to manage the foreign
expansion; the receipt of regulatory approvals or clearances
relating to the Triage business or the BNP business, or any loss of
previously received regulatory approvals or clearances; a
significant reduction in sales of the Triage business or BNP
business, or increase in costs, expenses or other charges incurred
by, relating to or arising from such businesses; the inability to
achieve anticipated financial results from the acquired businesses;
and the Company’s ability to successfully integrate the acquired
businesses into the Company’s operations, including its ability to
realize anticipated synergies and operational improvement.
Forward-looking statements are based on management’s expectations
as well as estimates and assumptions prepared by management that,
although they believe to be reasonable, are inherently uncertain.
The Company is subject to additional risks and uncertainties
described in the Company’s annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q. You are cautioned not to
place undue reliance on these forward-looking statements, which
reflect management’s analysis and expectations only as of the date
of this press release. We undertake no obligation to publicly
release the results of any revision or update of the
forward-looking statements, except as required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170928006191/en/
For Quidel CorporationRandy StewardChief Financial Officer(858)
552-7931orAngie Mazza(312) 690-6006amazza@clermontpartners.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024